Sap fc fusion proteins and methods of use

A method of treating an amyloid disease in an individual, comprising administering to the individual a fusion protein comprising a structure represented by the following formula:

• from N-terminus to C-terminus, SAP-Fc1-L1-Fc2, wherein Fc1 is a first Fc domain sequence comprising hinge-CH2-CH3, L1 is a linker, and Fc2 is a second Fc domain sequence comprising hinge-CH2-CH3, wherein SAP is a human serum amyloid P (SAP) component protein, wherein Fc1 and Fc2 each comprise amino acid substitutions C226S and C229S, according to EU numbering, wherein the fusion protein comprises the amino acid sequence set forth in SEQ ID NO:
• 1 with or without the C-terminal lysine, or SEQ ID NO:
• 23 with or without the C-terminal lysine.

(canceled)

(canceled)

A method of treating an amyloid disease in an individual, comprising administering to the individual a fusion protein comprising a structure represented by the following formula:

• from N-terminus to C-terminus, SAP-Fc1-L1-Fc2, wherein Fc1 is a first Fc domain sequence comprising hinge-CH2-CH3, L1 is a linker, and Fc2 is a second Fc domain sequence comprising hinge-CH2-CH3, wherein SAP is a human serum amyloid P (SAP) component protein, wherein Fc1 and Fc2 each comprise amino acid substitutions C226S and C229S, according to EU numbering, wherein the human SAP comprises the amino acid sequence set forth in SEQ ID NO:
• 20.